Satellos Advances in Duchenne Muscular Dystrophy Trial

Satellos Bioscience (TSE:MSCL) has released an update.

Satellos Bioscience has achieved a significant milestone by dosing the first patient with Duchenne muscular dystrophy (DMD) in their Phase 1b clinical trial of SAT-3247. This development follows the successful completion of earlier safety trials, indicating the drug’s potential as a safe and tolerable treatment option for DMD. The trial aims to enroll up to 10 participants to further assess the drug’s safety and pharmacokinetics.

For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.